California Public Employees Retirement System Has $12.32 Million Holdings in Glaukos Co. (NYSE:GKOS)

California Public Employees Retirement System lessened its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 4.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 82,192 shares of the medical instruments supplier's stock after selling 4,049 shares during the quarter. California Public Employees Retirement System owned about 0.15% of Glaukos worth $12,324,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Schroder Investment Management Group boosted its stake in Glaukos by 213.9% in the 4th quarter. Schroder Investment Management Group now owns 10,259 shares of the medical instruments supplier's stock worth $1,538,000 after purchasing an additional 6,991 shares during the period. Pictet Asset Management Holding SA boosted its stake in shares of Glaukos by 15.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 7,582 shares of the medical instruments supplier's stock valued at $1,137,000 after buying an additional 1,041 shares during the period. New Age Alpha Advisors LLC acquired a new stake in shares of Glaukos during the 4th quarter valued at $451,000. Norges Bank acquired a new stake in shares of Glaukos during the 4th quarter valued at $84,490,000. Finally, EFG Asset Management North America Corp. boosted its stake in shares of Glaukos by 106.7% during the 4th quarter. EFG Asset Management North America Corp. now owns 60,592 shares of the medical instruments supplier's stock valued at $9,102,000 after buying an additional 31,273 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Glaukos Stock Performance

NYSE GKOS traded down $5.13 during midday trading on Thursday, hitting $88.43. The company had a trading volume of 128,706 shares, compared to its average volume of 625,512. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a fifty day simple moving average of $116.82 and a two-hundred day simple moving average of $133.18. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71. The stock has a market cap of $5.00 billion, a price-to-earnings ratio of -30.88 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Equities analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on GKOS shares. Piper Sandler reissued an "overweight" rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Mizuho raised shares of Glaukos from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Wells Fargo & Company lifted their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus raised their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, December 31st. Finally, Citigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and raised their price target for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.